D Zheng, V Ionut, V Mooradian, D … - Diabetes, 2009 - Am Diabetes Assoc RESULTS— With hyperinsulinemia and hyperglycemia, exenatide produced a
significant increase in total glucose turnover by ∼30%, as indicated by portal
glucose infusion rate (saline 15.9 ± 1.6 vs. exenatide 20.4 ± 2.1 mg · ... Cited by 2 - Related articles - All 4 versions
S Park, SM Hong, SR Sung - Life sciences, 2007 - Elsevier Not only exendin-4 but also exercise has been reported to improve glucose
homeostasis by enhancing insulinotropic action, but the nature of its molecular
mechanism has not been clarified. We investigated a mechanism to promote ... Cited by 4 - Related articles - All 4 versions
- ►physiology.org K Johnson, DS Edgerton, T Rodewald, M Scott … - American Journal of Physiology- Endocrinology And …, 2008 - Am Physiological Soc After a meal, glucagon-like peptide-1 (GLP-1) and glucose levels are
significantly greater in the hepatic portal vein than in the artery. We have
previously reported that, in the presence of intraportal glucose delivery, ... Cited by 4 - Related articles - BL Direct - All 4 versions
[CITATION] Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor …
L Li, G Yang, Q Li, X Tan, H Liu, Y Tang, G … - Diabetes Obes Metab, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 6 - Related articles - All 2 versions
A Ceriello, S Colagiuri, J Gerich, J Tuomilehto - Nutrition, Metabolism and Cardiovascular Diseases, 2008 - Elsevier An estimated 246 million people worldwide have diabetes. Diabetes is a leading
cause of death in most developed countries, and is reaching epidemic proportions
in many developing and newly industrialized nations. Poorly controlled ... Cited by 6 - Related articles - All 11 versions
CA Sheffield, MP Kane, RS Busch, G Bakst, … - Endocrine Practice, 2008 - AACE Diabetes mellitus affects approximately 21 million Americans, including 90% to
95% with type 2 diabetes mellitus (T2DM) (1). Inadequately controlled diabetes
is associated with increased morbidity due to microvascular and ... Cited by 6 - Related articles - BL Direct - All 2 versions
CA Sheffield, MP Kane, RS Busch - Pharmacotherapy, 2007 - PPI Exenatide is an incretin mimetic indicated for the treatment of type 2 diabetes
mellitus in combination with a sulfonylurea, a thiazolidinedione, metformin, or
metformin plus a sulfonylurea or thiazolidinedione. Exenatide lowers ... Cited by 6 - Related articles - BL Direct - All 2 versions
A Vella, G Bock, PD Giesler, DB Burton, DB … - Clin Endocrinol (Oxf), 2008 - medscape.com Objectives: The incretin hormone glucagon-like peptide-1 (GLP-1) retards gastric
emptying and decreases caloric intake. It is unclear whether increased GLP-1
concentrations achieved by inhibition of the inactivating enzyme dipeptidyl ... Cited by 7 - Related articles - All 7 versions
